Showing results (231-240 of 270) with videos related to

Sort By:
Pageof 27
Blood|July 22, 2004
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialAntonio Palumbo, Sara Bringhen, Maria Teresa Petrucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.
Blood|February 26, 2005
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcomeMarco Ladetto, Sonia Vallet, Andreas Trojan, et al.
Blood|August 13, 2011
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomideAlessandra Larocca, Federica Cavallo, Sara Bringhen, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Hematological Oncology|September 30, 2022
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana LinfomiEmanuele Cencini, Alessandra Tucci, Benedetta Puccini, et al.
Hemasphere|May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trialFrancesca Cordero, Simone Ferrero, Simone Pernice, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Haematologica|November 17, 2022
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)Alessandra Tucci, Francesco Merli, Alberto Fabbri, et al.
Blood Advances|April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trialSimone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Pageof 27